Bicocca Open Archive

Logo unimib boa
CARBONE, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.586
EU - Europa 4.667
AS - Asia 2.067
SA - Sud America 28
AF - Africa 20
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 15.377
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.478
IT - Italia 1.333
SG - Singapore 821
DE - Germania 763
CN - Cina 632
IE - Irlanda 604
SE - Svezia 549
RU - Federazione Russa 512
GB - Regno Unito 324
HK - Hong Kong 284
CA - Canada 103
AT - Austria 98
UA - Ucraina 96
NL - Olanda 92
FI - Finlandia 77
TR - Turchia 76
FR - Francia 72
IN - India 71
ID - Indonesia 54
DK - Danimarca 44
VN - Vietnam 44
BE - Belgio 20
MY - Malesia 17
PT - Portogallo 16
JP - Giappone 13
KR - Corea 12
BR - Brasile 10
RO - Romania 10
TW - Taiwan 9
AR - Argentina 7
CZ - Repubblica Ceca 7
IL - Israele 7
LT - Lituania 7
PL - Polonia 7
SK - Slovacchia (Repubblica Slovacca) 7
CH - Svizzera 5
DZ - Algeria 5
ES - Italia 5
GR - Grecia 5
IR - Iran 5
AU - Australia 4
CL - Cile 4
EG - Egitto 4
GH - Ghana 4
MM - Myanmar 4
PK - Pakistan 4
RS - Serbia 4
EC - Ecuador 3
HU - Ungheria 3
NO - Norvegia 3
SA - Arabia Saudita 3
SC - Seychelles 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
MX - Messico 2
NZ - Nuova Zelanda 2
PE - Perù 2
ZA - Sudafrica 2
ZW - Zimbabwe 2
AZ - Azerbaigian 1
BD - Bangladesh 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
CO - Colombia 1
CR - Costa Rica 1
CY - Cipro 1
EE - Estonia 1
EU - Europa 1
GE - Georgia 1
GT - Guatemala 1
IQ - Iraq 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
PA - Panama 1
PH - Filippine 1
Totale 15.377
Salva come PNG Salva come JPEG
Città #
Ann Arbor 2.274
Singapore 699
Frankfurt am Main 661
Fairfield 634
Dublin 584
Chandler 569
Woodbridge 486
Wilmington 469
Milan 426
Houston 376
Ashburn 310
Santa Clara 306
New York 279
Hong Kong 270
Seattle 254
Dearborn 252
Cambridge 216
Princeton 214
Chicago 166
Jacksonville 147
London 135
Shanghai 123
Nanjing 104
Lawrence 103
Altamura 101
Vienna 94
Beijing 74
Rome 73
San Diego 71
Jakarta 54
Boardman 49
Helsinki 38
Florence 35
Toronto 31
Andover 29
Lachine 29
Lissone 27
Monza 27
Nanchang 24
Guangzhou 21
Los Angeles 21
Ottawa 21
Fremont 20
Pune 20
Bari 19
Brussels 19
Hangzhou 19
Turin 19
Hebei 17
Genoa 16
Munich 16
Penang 16
Changsha 15
Norwalk 15
Bologna 14
Mountain View 14
Paris 14
Kunming 13
Lisbon 13
Mumbai 13
Tianjin 13
Falls Church 12
Jinan 12
Jiaxing 11
Bedford 10
Rho 10
Seregno 10
Shenyang 10
Bergamo 9
Detroit 9
Dong Ket 9
Edmonton 9
Kocaeli 9
Amsterdam 8
Groningen 8
New Bedfont 8
Ningbo 8
Passignano sul Trasimeno 8
São Paulo 8
Brno 7
Buffalo 7
Council Bluffs 7
Desio 7
Lappeenranta 7
Zhengzhou 7
Bratislava 6
Central 6
Chengdu 6
Hefei 6
Kiev 6
Kilburn 6
Laurel 6
Naples 6
Padova 6
Tappahannock 6
Treviglio 6
Washington 6
Wenzhou 6
Zanica 6
Carate Brianza 5
Totale 11.480
Salva come PNG Salva come JPEG
Nome #
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 425
The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis 314
A worldwide cross-ethnic study of quality of life in patients with PBC: Attitude or latitude? 299
Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid 270
Autoimmune liver disease, autoimmunity and liver transplantation 258
Calcineurin inhibitors and the IL12A locus influence risk of recurrent primary biliary cirrhosis after liver transplantation 251
Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine 237
Quality of life in patients with primary biliary cholangitis: a cross-geographical comparison 226
Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak 223
Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis 211
FRI-008-Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study 194
FRI-006-Soluble CD163 and mannose receptor as markers of liver disease severity and long term prognosis in patients with primary biliary cholangitis 192
Female preponderance of primary biliary cholangitis is all about our understanding of its autoimmune nature 190
Precision medicine in primary biliary cholangitis 186
Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland 183
Accuracy of Liver Stiffness Measurement in assessing liver fibrosis in naïve patients with Primary Biliary Cholangitis 183
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 182
From pathogenesis to novel therapies in the treatment of primary biliary cholangitis 177
THU-010-Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis 177
Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach 176
Risk stratification in primary sclerosing cholangitis 176
Exploring the landscape of steatotic liver disease in the general US population 175
Endocrinology and Metabolic Diseases (Including Diabetes) 171
The challenges of primary biliary cholangitis: What is new and what needs to be done 169
FRI-011-Ductular reaction, intermediate hepatocites and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 168
Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies 167
Additive beneficial effects of Fibrates combined with Obeticholic acid in the treatment of patients with Primary Biliary Cholangitis and inadequate response to second-line therapy: data from the Italian PBC Study Group 166
Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach 165
Novel insights in primary biliary cholangitis (PBC) epidemiology using administrative records 162
A National Hospital‐Based Study of Hospitalized Patients With Primary Biliary Cholangitis 162
New Therapeutic Targets in Autoimmune Cholangiopathies 159
Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis 158
Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis 157
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 157
Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients 154
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 153
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 152
Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets 145
Leptin attenuates ischemia-reperfusion injury in the rat liver 144
Autoimmune liver diseases 143
Prognostic models in primary biliary cholangitis 137
Reply to: “A spotlight on natural killer cells in primary biliary cholangitis” 134
Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma 133
Genetics and epigenetics of primary biliary cirrhosis 133
Treatment of PBC-A step forward 133
The mode of dexamethasone decoration influences avidin-nucleic-acid-nano-assembly organ biodistribution and in vivo drug persistence 131
Hepatitis C virus and nonliver solid organ transplantation 128
Machine learning in primary biliary cholangitis: A novel approach for risk stratification 128
Cell and organ bioengineering technology as applied to gastrointestinal diseases 127
How regenerative medicine and tissue engineering may complement the available armamentarium in gastroenterology? 127
Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study 126
Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response 125
Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis 125
Late acute liver allograft rejection; A study of its natural history and graft survival in the current era 122
Geoepidemiology, Genetic and Environmental Risk Factors for PBC 121
Treatment discontinuation with peg-interferon: What to consider 121
Support of precision medicine through risk-stratification in autoimmune liver diseases - histology, scoring systems, and non-invasive markers 121
The "gut microbiota" hypothesis in primary sclerosing cholangitis 120
The immunobiology of female predominance in primary biliary cholangitis 120
Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis 119
The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort 116
Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis 115
The application of artificial intelligence in hepatology: A systematic review 113
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 111
An unusual endoscopic finding in a patient with melena: multiple gastric ulcers of regular shape 110
Liver Transplantation in the Clinic - Progress Made During the Last Three Decades 110
Reply to: "Fatigue and liver transplantation in patients with primary biliary cirrhosis" 109
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 107
Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study 107
Calcium channel blockers or angiotensin-converting enzyme inhibitors for de novo hypertension after liver transplant: and the winner is …? 106
Primary Biliary Cholangitis: advances in management and treatment of the disease 106
The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study 105
Prevention of hepatitis C recurrence after liver transplantation: An update 105
Risk stratification and prognostic modelling in primary biliary cholangitis 105
Cost of illness of Primary Biliary Cholangitis - a population-based study 105
Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history 103
Solid organ transplantation: has the promise been kept and the needs met? Solid Organ Transplantation in the Regenerative Medicine Era 101
Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis 100
Toward precision medicine in primary biliary cholangitis 100
Autoantibodies in patients with interleukin 12 receptor beta 1 deficiency 100
International comparison of liver transplant programmes: differences in indications, donor and recipient selection and outcome between Italy and UK 97
The epigenetics of PBC: The link between genetic susceptibility and environment 95
Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis 94
Comprehensive review of autoantibodies in patients with hyper-IgM syndrome 94
NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid 93
Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis 92
Primary sclerosing cholangitis: Burden of disease and mortality using data from the national rare diseases registry in Italy 91
Hepatitis C virus infection and diabetes: a complex bidirectional relationship 91
Identifying Racial Disparities in Primary Biliary Cholangitis Patients: A Step Toward Achieving Equitable Outcomes Among All 84
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 84
Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States 83
HLA haplotypes in primary sclerosing cholangitis patients of admixed and non-European ancestry 83
Management of patients with autoimmune liver disease during COVID-19 pandemic 81
Novel treatments targeting immune-related mechanisms in primary biliary cholangitis 80
Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe 79
Individualizing Care: Management Beyond Medical Therapy 79
Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists 75
Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase 74
Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitis 72
Impact of the new definition of metabolic dysfunction–associated fatty liver disease on detection of significant liver fibrosis in US adolescents 71
Totale 14.114
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.735
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.735
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020888 0 0 0 0 0 0 240 166 148 178 110 46
2020/20212.605 89 66 379 178 184 261 283 312 237 213 207 196
2021/20221.871 193 187 214 143 141 142 54 105 79 145 170 298
2022/20232.934 333 740 266 252 264 370 126 130 222 76 83 72
2023/20242.687 71 111 108 258 293 580 383 76 156 173 93 385
2024/20252.610 445 717 389 335 500 215 9 0 0 0 0 0
Totale 16.179